Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability 1; Fenebrutini ...
The actor’s ex-wife, Sarah Quinones, told TMZ on Tuesday that Haskins was in an assisted living facility at the end of his life.
Dennis Haskins privately battled Parkinson's disease for eight years before his death, according to his caretaker. Sarah ...
The FDA has approved Juvmo, an oral tavapadon treatment for adults with Parkinson’s disease, following three pivotal phase 3 ...
Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...
A small pilot trial, the first to assess time-restricted eating in Huntington disease, shows the safety and tolerability of ...
On Monday, Sept. 28, the U.S. Food and Drug Administration approved a new treatment that targets dopamine pathways critical to those living with the disease.
AbbVie ( ABBV) announced that the U.S. FDA has approved JUVMO (tavapadon) tablets for the treatment of adults with Parkinson's disease, providing a new oral treatment option for a progressive ...
AbbVie's Juvmo (tavapadon) receives FDA approval as the first selective D1/D5 agonist for Parkinson's disease treatment.
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
AbbVie (ABBV) wins FDA approval for Juvmo, a first-in-class Parkinson's disease treatment targeting D1/D5 receptors, ...
AbbVie (ABBV) gains FDA approval for Juvmo, a first-in-class Parkinson's treatment launching October 2026. Stock dips 0.29% despite breakthrough.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results